HNSBF News Today: Stay Updated with the Latest Hansa Biopharma AB (publ) News in Real Time
Find HNSBF news now at Meyka AI. Stay informed with the latest Hansa Biopharma AB (publ) stocks updates, including price news, market analysis, and expert insights.
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%
GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion. GSK Plc stock…
IMMX Maintained at Buy by H.C. Wainwright, May 2026
H.C. Wainwright maintains Buy rating on IMMX, raises price target to $20 from $15 on May 22, 2026.
LBGUF Earnings Beat: L E Lundbergföretagen Q2 2026 Results
LBGUF reported Q2 2026 earnings on May 21, 2026 with $2.02 EPS and $868.45M revenue. Meyka AI rates the stock B+.
Xvivo Perfusion AB (XVIPY) Holds $6.54 as Organ Transplant Tech Faces Valuation Pressure
XVIPY stock trades flat at $6.54 USD on PNK. Medical device company faces high valuation multiples despite strong 6-month gains of 40%.
BRCTF Earnings Beat: BioArctic AB (publ) Crushes Q2 2026 Estimates
BioArctic AB (BRCTF) beat Q2 2026 earnings on May 20 with EPS of $0.2514 vs. -$0.0316 estimate and $46.04M revenue vs. $20.26M expected.
Sunshine Biopharma (SBFM) Surges 15.6% on $6 Million Offering Close
SBFM stock jumps 15.6% to $0.51 after Sunshine Biopharma closes $6 million public offering. Trading volume surges 34x average.
NDRBF Earnings Beat: NIBE Industrier Q2 2026 Results
NDRBF beats EPS and revenue estimates in Q2 2026 earnings. NIBE Industrier reports $0.0263 EPS vs $0.0257 estimate, $1.02B revenue.
Beyond Frames Entertainment Stock Slips 1.9% Ahead of Earnings
8WP.F stock drops 1.9% to €0.207 on XETRA ahead of May 21 earnings announcement. Gaming firm faces profitability challenges.
Xvivo Perfusion AB (XVIPY) Holds $6.54 as Organ Transplant Tech Faces Valuation Pressure
XVIPY stock trades flat at $6.54 USD. Medical device maker faces elevated valuation metrics and mixed analyst outlook in healthcare sector.